A Phase 1/2 interventional study of ecnoglutide tablets and placebo with matching dosage in Overweight and/or Obesity and Weight Management, sponsored by Hangzhou Sciwind Biosciences Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Hangzhou Sciwind Biosciences Co., Ltd. · Phase 1/2, Interventional, and Treatment
oral ecnoglutide C1 · oral ecnoglutide C2 · oral ecnoglutide C3 · oral ecnoglutide C4 · oral ecnoglutide C5 · oral ecnoglutide C6
oral ecnoglutide dose 1 · oral ecnoglutide dose 2 · oral ecnoglutide dose 3 · oral ecnoglutide dose 4 · placebo dose 1 · placebo dose 2
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd. — 7 open to participants now, 8 under way, 4 of them phase 3. Obesity · Hangzhou Sciwind Biosciences Co., Ltd..
Among the 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd., this one is the 8th largest by planned enrollment, is one of 3 that started in 2025, is the only one in phase 1/2, and was the 4th registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →7 of the 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–75
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–75
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–75
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–65
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 5
First in 2023; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 126 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 152 across the 10 interventional studies. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hangzhou Sciwind Biosciences Co., Ltd. is the lead sponsor of 15 studies on the registry; 7 are open to participants now.
4 of the studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07243171Hangzhou Sciwind Biosciences Co., Ltd.A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity | 2027-01-05 |
| NCT07073417Hangzhou Sciwind Biosciences Co., Ltd.A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH) | 2027-02-27 |
| NCT07936058Hangzhou Sciwind Biosciences Co., Ltd.A Phase I Study to Evaluate the Food Effect on Ecnoglutide Tablet | 2027-04-15 |
| NCT07929298Hangzhou Sciwind Biosciences Co., Ltd.A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity | 2027-09-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ecnoglutide tablets in Chinese participants with overweight or obesity
In this study, eligible participants will be randomized to receive either oral ecnoglutide tablet or placebo once daily for up to 3 weeks (Cohort C1) or 4 weeks (Cohort C2 or C6), or once weekly for up to 24 weeks (Cohort C3, C4 and C5), including a dose escalation period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
once daily, up-titration every 7 days, dosing for 21 days in total
Drug: ecnoglutide tablets · Drug: placebo with matching dosage
once daily, up-titration every 7 days, dosing for 28 days in total
Drug: ecnoglutide tablets · Drug: placebo with matching dosage
once weekly, up-titration every 2-4 weeks, dosing for 24 weeks in total
Drug: ecnoglutide tablets · Drug: placebo with matching dosage
once weekly, up-titration every 2-4 weeks, dosing for 24 weeks in total
Drug: ecnoglutide tablets · Drug: placebo with matching dosage
once weekly, up-titration every 4 weeks, dosing for 24 weeks in total
Drug: ecnoglutide tablets · Drug: placebo with matching dosage
once daily, up-titration every 7 days, dosing for 28 days in total
Drug: ecnoglutide tablets · Drug: placebo with matching dosage
oral tablets, once daily
oral tablets, once daily
oral tablets, once weekly
oral tablets, once weekly
The incidence and severity of adverse events
Time frame: up to day 204
Pharmacokinetics of oral ecnoglutide tablet
Cmax, Tmax and AUC
Time frame: up to day 204
Change of body weight from baseline
Time frame: up to day 204
Change of BMI from baseline
Time frame: up to day 204
Change of waist circumference from baseline
Time frame: up to day 204
Change of hip circumference from baseline
Time frame: up to day 204
Change of neck circumference from baseline
Time frame: up to day 204
Change of waist/hip ratio from baseline
Time frame: up to day 204
Change of fasting blood glucose from baseline
Time frame: up to day 204
Change of fasting insulin from baseline
Time frame: up to day 204
Change of lipid profile from baseline
Time frame: up to day 204
anti-drug antibody
ADA of ecnolgutide
Time frame: up to day 204
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Jan 2027, 13 months after the start.
Of 62 phase 1/2 interventional studies under Obesity, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's planned 13 months is below that.
How these figures are worked out, and which studies are left out of them.
oral ecnoglutide C1 · oral ecnoglutide C2 · oral ecnoglutide C3 · oral ecnoglutide C4 · oral ecnoglutide C5 · oral ecnoglutide C6
oral ecnoglutide dose 1 · oral ecnoglutide dose 2 · oral ecnoglutide dose 3 · oral ecnoglutide dose 4 · placebo dose 1 · placebo dose 2
oral ecnoglutide C1 · oral ecnoglutide C2 · oral ecnoglutide C3 · oral ecnoglutide C4 · oral ecnoglutide C5 · oral ecnoglutide C6
oral ecnoglutide dose 1 · oral ecnoglutide dose 2 · oral ecnoglutide dose 3 · oral ecnoglutide dose 4 · placebo dose 1 · placebo dose 2
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ecnoglutide
Hangzhou Sciwind Biosciences Co., Ltd.